A Phase IA, Multicenter, Open-label Dose Escalation Study of BKM120, Administered Orally in Adult Patients With Advanced Solid Malignancies.
Phase of Trial: Phase I
Latest Information Update: 12 Mar 2014
At a glance
- Drugs Buparlisib (Primary)
- Indications Solid tumours
- Focus Adverse reactions; First in man
- Sponsors Novartis
- 22 Feb 2012 Planned number of patients changed from 86 to 83 as reported by ClinicalTrials.gov.
- 22 Feb 2012 Planned end date changed from 1 Sep 2011 to 1 Dec 2012 as reported by ClinicalTrials.gov.
- 22 Feb 2012 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.